Clinical Trial

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

Name: Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) — clinical trial record (NCT07389278)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is an open label, intra-patient dose escalation, to evaluate ADI-PEG 20, in combination with Temozolomide (TMZ) and radiation therapy (RT) in children, adolescents and young adult patients with newly diagnosed high grade glioma (HGG).

Trial Details

NCT Number	NCT07389278
Lead Sponsor	Sabine Mueller, MD, PhD
Conditions	Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Hemispheric Glioma, H3G34 Mutant
Enrollment	97 participants
Start Date	2026-03-09
Primary Completion	2032-06-30 (estimated)
Study Completion	2035-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-02-05